Nilogen Oncosystems partners with pharmaceutical and biotech companies in oncology drug development. Our ex vivo platform utilizes 3D tumoroids prepared from fresh patient tissue without any dissociation, propagation, or reassembly. This ensures an intact tumor immune microenvironment to accurately assess the therapeutic potential of drug treatments. Our 3D-EXplore platform enables investigation of therapeutic efficacy, mechanism of action, biomarker discovery, along with the enhancement of clinical trial enrollment. Capabilities include confocal microscopy, flow cytometry, cytokine analysis, next generation sequencing, and immunohistochemistry. Additionally, our 3D-EXpress platform leverages our extensive fully characterized tumoroid biorepository to support rapid efficacy studies and clinically relevant data generation.

Nilogen has over ten years’ experience working with small molecules, antibody therapeutics, cell therapies, and oncolytic viruses.